Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Pulmonx ( (LUNG) ) is now available.
On October 27, 2025, Pulmonx Corporation announced significant leadership changes with the reappointment of Glen French as President and CEO, and the appointment of Derrick Sung as COO and CFO. Concurrently, Steve Williamson and Mehul Joshi resigned from their roles but will remain in advisory capacities until December 1, 2025, to ensure a smooth transition. The company also reported preliminary third-quarter revenue of approximately $21.5 million and rescheduled its earnings call to November 12, 2025. These changes are expected to leverage French’s extensive experience to drive future growth and stability for Pulmonx.
The most recent analyst rating on (LUNG) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Pulmonx stock, see the LUNG Stock Forecast page.
Spark’s Take on LUNG Stock
According to Spark, TipRanks’ AI Analyst, LUNG is a Neutral.
Pulmonx’s financial performance is the most significant factor, with ongoing profitability and cash flow challenges. Technical analysis indicates a bearish trend, and valuation is weak due to negative earnings. The earnings call provides a balanced view, with strong international growth but challenges in the U.S. market.
To see Spark’s full report on LUNG stock, click here.
More about Pulmonx
Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The company offers products such as the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Reports, which are designed to treat patients with severe emphysema/COPD. The Zephyr Valve has received FDA pre-market approval and is commercially available in over 25 countries.
Average Trading Volume: 580,221
Technical Sentiment Signal: Sell
Current Market Cap: $66.82M
For a thorough assessment of LUNG stock, go to TipRanks’ Stock Analysis page.